GLP-1 & compounded medication availability in Kentucky (2026)

Kentucky’s pharmacy regulator has put more in writing about compounded GLP-1s than most states: standing guidance, a November 2025 compliance alert, and a sourcing order for pharmacies buying from outsourcing facilities. Here is what actually ships to Kentucky addresses across all ten product lines we track, with the state’s own documents cited below.

Conditional state

Availability facts last reviewed: November 16, 2026

What ships to Kentucky: all ten lines

Availability of all ten OrderlyMeds product lines in Kentucky, with typical delivery times and notes
Product lineAvailable in Kentucky?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships from licensed partner pharmacies under a patient-specific prescription.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same flat national price at every dose.
NAD+ Yes 8–10 business days Longevity line; same ordering flow.
Sermorelin Yes 8–10 business days Ships from licensed partner pharmacies.
Glutathione No N/A Not in the OrderlyMeds formulary today.
BPC-157 Yes 8–10 business days Compounded injectable. Its federal record is below.
TB-500 Yes 8–10 business days Compounded injectable; see its section below.
KPV No N/A Not carried, since our peptide lines are injectables only.
Epitalon Yes 8–10 business days Compounded injectable; federal picture below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record is its own, below.

A “No” above is a real answer, not a gap in the table. Kentucky facts on this page were last reviewed on November 16, 2026.

Research peptides in Kentucky: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Four of these five ship to Kentucky addresses as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV is the exception, because we compound these lines as injectables only and KPV is not one of them. Kentucky is worth reading carefully here: the federal peptide case law literally ran through this state (see the regulator section below), and each line’s own federal record follows its heading, stated whether or not the line ships to you.

BPC-157 in Kentucky

Ships to Kentucky addresses as a compounded injectable, filled under a patient-specific prescription. Kentucky’s own enforcement history on this substance, and the two federal facts below, are part of the honest picture.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Kentucky

Available to Kentucky addresses as a compounded injectable under a patient-specific prescription. The federal facts below apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Kentucky

We do not ship KPV to Kentucky, or anywhere. Our peptide lines are compounded as injectables, and KPV is not among them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Kentucky

In the formulary for Kentucky as a compounded injectable, dispensed on a patient-specific prescription. Its federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Kentucky

MOTS-c ships to Kentucky addresses as a compounded injectable on a patient-specific prescription. Its federal record below is its own, not a copy of the other four.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Kentucky’s pharmacy regulators say about compounded medications

Kentucky’s pharmacy regulator is one of the more vocal in the country on this subject. Rather than leaving licensees to read federal policy on their own, it has published its own compounding guidance, followed it with a compliance alert in late 2025, and tied both to its disciplinary authority. None of that creates a Kentucky-only restriction on any line this page tracks, since the state’s paper trail restates the federal framework, but it signals a regulator that reads shipping manifests, not just rulebooks.

The board’s 2025 compounding guidance states that compounding pharmacies in general may not compound semaglutide or tirzepatide, which are commercially available drug products, and cites 201 KAR 2:076 — the state rule prohibiting compounded copies of a commercially available drug product unless authorized under 21 U.S.C. 353(a) — as enforceable against anyone licensed or permitted by the Commonwealth. Source: Kentucky Board of Pharmacy — Compounding Semaglutide and Tirzepatide (2025).

A board compliance alert dated November 14, 2025 states that the patient-specific clinical-difference exception exists only in section 503A compounding, that 503B outsourcing facilities generally may not lawfully compound semaglutide or tirzepatide now that neither drug appears on FDA’s shortage list or the 503B bulks lists, and that any permitted pharmacy dispensing unapproved drug products to patients in the Commonwealth, unless authorized by law, may be subject to disciplinary action. Source: Kentucky Board of Pharmacy — Compounded Semaglutide and Tirzepatide Compliance Alert (Nov. 14, 2025).

Kentucky is also where federal peptide enforcement has already happened once: in 2020, a Nicholasville compounding pharmacy and its owner pleaded guilty in the Eastern District of Kentucky to distributing unapproved peptide drugs — BPC-157 and Epitalon among them — and to wholesale distribution of prescription drugs without the required board license, forfeiting about $1.79 million. That case predates HHS’s October 2026 enforcement-discretion policy, which now defines a conditional, route-limited federal pathway for six named peptides. Source: U.S. Attorney’s Office, E.D. Ky. — sentencing announcement.

Kentucky permits prescribing on the basis of a telehealth encounter that meets the state’s standard of care; no prior in-person visit is required for the medication categories on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

In practice, a Kentucky order runs the same path as any other OrderlyMeds order: an online eligibility check, an evaluation by a Kentucky-licensed provider, and fulfillment by a licensed partner pharmacy shipping into the state under a patient-specific prescription, which is exactly the compounding model the documents above describe. Pricing is national, so the number on our pricing page is the Kentucky number.

Kentucky availability FAQs

Is compounded semaglutide available in Kentucky?

Yes. OrderlyMeds ships compounded semaglutide to Kentucky addresses under a patient-specific prescription, within the narrow federal path the state regulator’s guidance describes. New customers start at $74/month for the first two months.

Do I need to see a doctor in person to get started in Kentucky?

No. Your evaluation happens by telemedicine with a Kentucky-licensed provider. The cited regulator section above covers the state’s telehealth position.

Can I get BPC-157 or other research peptides shipped to Kentucky?

BPC-157, TB-500, Epitalon and MOTS-c ship to Kentucky as compounded injectables under patient-specific prescriptions; KPV does not, because our peptide lines are injectables only. Each section above states that substance’s own federal record, including the FDA safety position that applies wherever you buy.

How long does delivery to Kentucky take?

Our published window is 8–10 business days from signup to delivery at a Kentucky address.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone